SCHEMBL6661929

SCHEMBL6661929

Cc1ccncc1-n1ccc2c(-c3cccc([N+](=O)[O-])c3)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.42
CHRNB2 P17787 1/20 0.40
CHRNA5 P30532 1/20 0.40
CHRNA4 P43681 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 6/20 0.39
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 3/20 0.39
THRB P10828 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPC1 O15118 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GSK3B P49841 1/20 0.39
QPCT Q16769 1/20 0.39
PDE4A P27815 2/20 0.38
PDE4D Q08499 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656880 0.82 CHRNB2 (0.43) CHRNB2CHRNA5CHRNA4MAPTRAB9A
SCHEMBL6656515 0.82 CYP17A1 (0.47) CYP1A2
SCHEMBL6845459 0.81 DHODH (0.41) MAPTCYP1A2GSK3BQPCT
SCHEMBL6661647 0.81 MAPK14 (0.44) MAPTRAB9ANPC1CYP1A2CYP3A4
SCHEMBL6657600 0.79 CYP11B1 (0.43) CHRNB2CHRNA5CHRNA4ALDH1A1TDP1
SCHEMBL6840591 0.77 CYP17A1 (0.52) CYP1A2
SCHEMBL6844416 0.75 CDC7 (0.41) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6845971 0.74 SETD7 (0.41) CYP1A2
SCHEMBL6844285 0.74 CYP11B2 (0.42) CYP1A2
SCHEMBL4504780 0.72 PDE4D (0.50) METCHRNB2CHRNA5CHRNA4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed
EP-1432698-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027094-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 MET 3547/4885CHRNB2 3541/4885CHRNA5 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.